Robert DeLuccia | Executive Chairman
Acurx Pharmaceuticals

Currently, Mr. DeLuccia is Executive Chairman of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), a New York-based, late development-stage biopharmaceutical company which he co-founded in 2017 and is focused on developing a new class of antibiotics, DNA pol IIIC inhibitors, to treat common infections caused by certain Gram-positive bacteria and to combat the global crisis of antimicrobial resistance (AMR) to currently available antibiotics. Acurx recently completed a successful End-of-Phase 2 Meeting with FDA and confirmed Phase 3 readiness for ibezapolstat, its lead product candidate, to enter Phase 3 clinical trials for the treatment of C. difficile infection. Agreement was also reached with FDA on the complete non-clinical and clinical development plan for filing of a New Drug Application (NDA) for marketing approval and in parallel, plans to submit requests for regulatory guidance to initiate clinical trials in the European Union, the United Kingdom, Japan and Canada. He has over 50 years’ executive and hands-on experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Mr. DeLuccia has held senior executive positions in both companies and has also been Chief Executive Officer of two publicly traded (Nasdaq) biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP). He was formerly Executive Chairman of publicly-traded (Nasdaq) Dipexium Pharmaceuticals, Inc., a New York-based, antibiotic development-stage biopharmaceutical company which he Co-Founded and subsequently took public. In April 2017, Dipexium closed a merger with PLx Pharma Inc. (PLXP-Nasdaq), a late-stage specialty pharmaceutical company focused on developing Aspertec™, its aspirin product in its proprietary PLxGuard™ drug delivery system to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy and better tolerated treatment. His therapeutic areas of marketing experience include new product introductions and drug development in the following areas: antibiotics (doxycycline, bacampicillin, cefaperazone) and antidiabetic agents (chlorpropamide and glypizide); and cardiovasculars (prazosin, amrinone; clopidogrel) and iohexol contrast media. New drug development areas included: topical creams/gels for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection. He is a former member of the Board of Directors of IBEX Pharmaceuticals, a publicly- traded (IBT.V/TSXV.IBT), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use and arthritis assays widely used in osteoarthritis research, which was recently acquired by BBI US Group LLC. Mr. DeLuccia received his undergraduate degree and MBA from Iona University, New York.   Military Service, Officer, U.S. Army Corps of Engineers.